Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
Chinese Social Media Giant Xiaohongshu Eyes Hong Kong IPO at Over $70 Billion Valuation 
BHP Shares Fall as Jansen Potash Project Costs Surge 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
GM and Lockheed Martin Partner to Strengthen U.S. Defense Manufacturing Capacity 
Microsoft Taps AWS to Support GitHub Amid AI Coding Boom 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
Jio IPO Filing Nears as Reliance Targets $4 Billion Market Debut 
SpaceX Surpasses Amazon in Market Value as Post-IPO Rally Accelerates 
SoftBank Shares Drop as OpenAI Losses and Rising Costs Spark Investor Concerns 
Frank Stronach Found Guilty of Sexual Assault and Indecent Assault in Ontario Court 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
Trump Says Anthropic No Longer Seen as National Security Threat 
WALTHAM, Mass., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced that Adam Gridley, President and Chief Executive Officer of Histogenics, will present at the 8th Annual Biotech Showcase™ Conference on Monday, January 11, 2016 at 11:30 AM PST at the Parc 55 Hotel in San Francisco, CA.
This presentation will be webcast live and may be accessed by visiting the Investor Relations section of Histogenics’ website at www.histogenics.com. The webcast will be available on Histogenics’ website for 30 days following the conference.
The Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences. Now in its eighth year, this rapidly growing conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase delegates include investors in private and public companies, sector analysts, bankers and industry professionals, as well as biopharmaceutical and life science company executives.
About Histogenics Corporation
Histogenics is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal segment of the marketplace. Histogenics’ regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions that can be utilized individually or in concert to treat musculoskeletal-related conditions. Histogenics’ first investigational product candidate, NeoCart®, leverages its platform to provide an innovative treatment in the orthopedic space, specifically cartilage damage in the knee.
Contact: Investor Relations Tel: +1 (781) 547-7909 [email protected]
